Q1 2025 Earnings Estimate for Arcadia Biosciences, Inc. (NASDAQ:RKDA) Issued By HC Wainwright

Arcadia Biosciences, Inc. (NASDAQ:RKDA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Arcadia Biosciences in a report released on Thursday, May 23rd. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will earn ($0.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Arcadia Biosciences’ current full-year earnings is ($5.01) per share. HC Wainwright also issued estimates for Arcadia Biosciences’ Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.43) EPS.

RKDA has been the subject of several other research reports. StockNews.com began coverage on Arcadia Biosciences in a research note on Thursday. They set a “sell” rating for the company. Lake Street Capital raised Arcadia Biosciences to a “strong-buy” rating in a research report on Tuesday, May 14th.

Arcadia Biosciences Price Performance

Arcadia Biosciences stock opened at $2.93 on Friday. Arcadia Biosciences has a one year low of $1.85 and a one year high of $5.60. The company’s fifty day moving average price is $2.26 and its two-hundred day moving average price is $2.61. The company has a market capitalization of $3.98 million, a price-to-earnings ratio of -0.57 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) EPS for the quarter, topping the consensus estimate of ($2.52) by $0.74. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.20 million. During the same quarter in the prior year, the business posted ($3.83) EPS.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.